B-Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor-T–Cell Therapy for Relapsed or Refractory AL Amyloidosis
Journal of the American Society of Nephrology · 2026-10 · 37 (10) · 2236-2247
DOI: 10.1681/asn.0000001096 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 01.04.2026. Verfasst von Xianghua Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Antigens, CD19, B-Cell Maturation Antigen, Immunoglobulin Light-chain Amyloidosis, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Provincial Key Research and Development Program, Basic Research Program of Jiangsu, National Natural Science Foundation of China.
Abstract (Originalsprache)
Key Points This study evaluated the safety and efficacy of B -cell maturation antigen-CD19 dual-targeted chimeric antigen receptor- T –cell therapy for patients with relapsed/refractory AL amyloidosis. B -cell maturation antigen-CD19 dual-targeted chimeric antigen receptor- T –cell therapy was well tolerated and no dose limiting toxicity occurred. Single-cell analysis confirmed B -cell maturation antigen-CD19 chimeric antigen receptor- T –cell enabled complete elimination of pathogenic plasma and B cells and promoted immune reconstitution.
Background
The potential efficacy of chimeric antigen receptor (CAR)- T cells for the treatment of relapsed/refractory systemic light chain (AL) amyloidosis remains elusive. This study aimed to investigate the efficacy and safety of B -cell maturation antigen (BCMA)-CD19 dual-targeted CAR- T –cell therapy in patients with refractory/relapsed AL amyloidosis in a single-center exploratory trial.
Methods
The key eligibility criteria of this trial were patients with AL amyloidosis and at least one major organ involvement who were refractory to or had relapsed from at least two lines of therapy. The primary outcome was the safety of CAR- T therapy. All eligible patients received a single infusion of 0.3×10 6 /kg the BCMA-CD19 dual-targeted CAR- T cells after preconditioning with fludarabine (30 mg/m 2 per day for 3 days) and cyclophosphamide (300 mg/m 2 per day for 3 days).
Results
Notably, six patients with refractory/relapsed AL amyloidosis were enrolled, all of whom had kidney involvement, and one of whom had cardiac involvement with Mayo stage 3a disease. After a median follow-up of 640 (range, 563–745) days, all six patients achieved hematologic complete response (100%, 95% confidence interval, 54% to 100%) and renal response (100%, 95% confidence interval, 54% to 100%). The median time to hematologic response and renal response were 9 (interquartile range, 6–11) and 75 (interquartile range, 18–180) days, respectively. One patient relapsed at month 6, while the other patients remained in remission. Grade 1 cytokine release syndrome occurred in two patients, and no immune effector cell–associated neurotoxicity syndrome was identified. Pneumonia occurred in two of the six patients. One patient had grade 3 urticaria and grade 2 AKI. One patient developed acute promyelocytic leukemia 15 months post–CAR- T –cell therapy. Single-cell RNA/ B -cell receptor sequencing confirmed that BCMA-CD19 dual-targeted CAR- T cells enabled the comprehensive clearance of pathogenic plasma cells and aberrant B cells, while also promoting endogenous immune reconstitution in AL amyloidosis.
Conclusions
This study provides preliminary evidence for the feasibility and tolerability of BCMA-CD19 dual-targeting CAR- T –cell therapy, and it showed promising activity in patients with relapsed/refractory AL amyloidosis. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05978661.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Shanghai Fosun Kairos Biotechnology Co., Ltd., Shanghai, China.
ORCID-Profile: Xianghua Huang, Xiaomei Wu, Wencui Chen, Weiwei Xu, Chris Wang, Zhihong Liu
Förderung
- Jiangsu Provincial Key Research and Development Program
- Basic Research Program of Jiangsu
- National Natural Science Foundation of China
Zitieren
APA
Huang, X., Wu, X., Chen, W., Wang, W., Xu, W., Guo, J., Zhao, J., Xu, X., Wang, C., Shan, A., Xu, J., & Liu, Z. (2026). B-Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor-T–Cell Therapy for Relapsed or Refractory AL Amyloidosis. Journal of the American Society of Nephrology, 37(10), 2236-2247. https://doi.org/10.1681/asn.0000001096
Vancouver
Huang X, Wu X, Chen W, Wang W, Xu W, Guo J, et al. B-Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor-T–Cell Therapy for Relapsed or Refractory AL Amyloidosis. Journal of the American Society of Nephrology. 2026;37(10):2236-2247. doi:10.1681/asn.0000001096
BibTeX
@article{Huang2026,
author = {Huang, Xianghua and Wu, Xiaomei and Chen, Wencui and Wang, Wenshi and Xu, Weiwei and Guo, Jinzhou and Zhao, Jinghua and Xu, Xiaodong and Wang, Chris and Shan, Aidong and Xu, Jiawei and Liu, Zhihong},
title = {B-Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor-T–Cell Therapy for Relapsed or Refractory AL Amyloidosis},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {10},
pages = {2236--2247},
doi = {10.1681/asn.0000001096}
}
EUVIMED